Cat. No. | Product name | CAS No. |
DC5090 |
WZ4002
Featured
WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM; does not inhibit ERBB2 phosphorylation (T798I). |
1213269-23-8 |
DC1097 |
XL-184 (Cabozantinib,BMS907351)
Featured
XL184 (Cabozantinib) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively. |
849217-68-1 |
DC3129 |
xl647
XL647 is a novel spectrum-selective kinase inhibitor for EGFR, ErbB2, KDR, Flt-4 and EphB4 with IC50 of 0.3 nM, 16 nM, 1.5 nM, 8.7 nM and 1.4 nM, respectively. |
781613-23-8 |
DC9941 |
XMD16-5
Featured
XMD16-5 is a novel TNK2 inhibitor. |
1345098-78-3 |
DC9940 |
XMD8-87
Featured
XMD8-87 is a novel TNK2 inhibitor. |
1234480-46-6 |
DC9446 |
Y15
Featured
Y15 is a novel small molecule FAK phosphorylation inhibitor; specifically block phosphorylation of Y397-FAK and total phosphorylation of FAK. |
4506-66-5 |
DC11471 |
BGB-3111(Zanubrutinib)
Featured
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor. |
1691249-45-2 |
DC8871 |
ZM 323881 HCl
ZM 323881 hydrochloride is a potent and selective inhibitor of human Flk-1 (vascular endothelial growth factor receptor 2, VEGFR-2/KDR) activity. |
193001-14-8 |
DC1082 |
ZM306416
Featured
ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist. |
690206-97-4 |
DC1083 |
ZM323881 hydrochloride
ZM323881 a receptor tyrosine kinase inhibitor of VEGFR-2 (Flk-1), PDGFR-beta, EGFR, and FGFR1 |
193000-39-4 |
DC10764 |
Theliatinib (HMPL-309)
Featured
Theliatinib (HMPL-309) is a novel small molecule, EGFR tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities. |
1353644-70-8 |
DC7376 |
BMS777607
Featured
BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM. |
1025720-94-8 |
DC7763 |
NVP-AST487
Featured
AST 487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. |
630124-46-8 |
DC11089 |
TAS-120 (Futibatinib)
Featured
TAS-120 is a highly potent and selective irreversible FGFR inhibitor, effective in tumors harboring various FGFR gene abnormalities. |
1448169-71-8 |
DC12371 |
XL-999(Tyrosine kinase-IN-1)
Featured
XL999, a Spectrum Selective Kinase Inhibitor(TM) (SSKIs), is a potent inhibitor of key RTKs implicated in the development and maintenance of tumor vasculature and in the proliferation of some tumor cells. |
705946-27-6 |
DC7052 |
AG-1024 (Tyrphostin)
Featured
AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, less potent to IR with IC50 of 57 μM. |
65678-07-1 |
DC12161 |
TAS6417
Featured
TAS6417 is an EGFR inhibitor and an efficacious drug candidate for patients with NSCLC, with IC50 values ranging from 1.1-8.0 nM. |
1661854-97-2 |
DC11689 |
RU-301
Featured
RU-301 (RU301) is a small molecule pan-TAM inhibitor that targets the TAM Ig1-Gas6 interface, blocks Gas6-dependent TAM activation. |
1110873-99-8 |
DC11450 |
Selpercatinib(LOXO-292)
Featured
Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively. Antineoplastic activity. |
2152628-33-4 |
DC7622 |
BIBX1382
Featured
BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM). |
196612-93-8 |
DC28032 |
EMI1 (EGFR MaMTH Inhibitor 1)
Featured
EMI1 (EGFR MaMTH Inhibitor 1) is a novel EGFR ex19del/T790M/C797S inhibitor.EMI1, while potently reducing the interaction of EGFR triple mutant with Shc1 in our MaMTH-DS assay, did not behave as a TKI and displayed no inhibition of the kinase activity of EGFR triple-mutant protein invitro.EMI1 did, however, more strongly inhibit the viability and increase the caspase 3/7 activ-ity of PC9 EGFR ex19del/T790M/C797S triple-mutant cells than noncancerous human bronchial epithelial (HBE) cells, as well as potently reduce PC9 EGFR ex19del/T790M/C797S organ-oid viability.EMI1 had a similar inhibi-tory effect on microtubule plus-end growth in both EGFR-WT and EGFR-C797S triple-mutant cells at 50–100 nM concentration. At 1 µM concentration, EMI1 strongly depolymerized inter-phase microtubules, perturbed spindle formation and induced strong mitotic block in PC9 EGFR ex19del/T790M/C797S cells after 20 h of treatment. EMI1 inhibited interaction of both proteins with EGFR at a level similar to that observed with Shc1, indicating it is not a specific inhibitor of the EGFR-Shc1 PPI interface. Rather, the loss of interaction mediated by EMI1 appears to be due to a more general alteration in EGFR activity.EMI1 induced EGFR degradation, and inhibited the activation of EGFR, ERK, AKT and S6 in PC9-ex19del and PC9-ex19del/T790M cells. |
35773-42-3 |
DC28069 |
O-Desmethyl gefitinib
O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity. O-desmethyl gefitinib inhibits EGFR with an IC50 of 36 nM in subcellular assays. |
847949-49-9 |